Sylvant 100 mg & 400 mg Powder for concentrate for solution for infusion)
PDF Leaflet Revision Date: 21 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multicentric Castlemanu2019s disease (MCD) in HIV-negative and HHV-8-negative patients.
Dosage (summary)
11 mg/kg IV infusion every 3 weeks.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not established in breastfeeding.
Key Drug Interactions
- CYP450 substrates
- Warfarin
- Ciclosporin
- Theophylline
Contraindications
- Severe hypersensitivity
- Pregnancy
Common side effects
- Upper respiratory tract infection
- Pruritus
- Rash
- Arthralgia
- Diarrhoea
Counselling Points
- Monitor for infections
- Avoid live vaccines
- Use contraception during treatment
Serious warnings
- Serious infections
- Infusion related reactions
- Gastrointestinal perforation
- Increased risk of malignancy
Important Disclaimer
The Sylvant 100 mg & 400 mg Powder for concentrate for solution for infusion) professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
